

Claims:

1. A calcium or a magnesium salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)-amino]-2-oxoethoxy}phenyl)propanoic acid.
- 5 2. A calcium salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid.
- 10 3. A salt as claimed in either claim 1 or claim 2 which may be a solvate, a hydrate, a mixed solvate/hydrate, an ansolvate or an anhydrate.
- 15 4. A salt as claimed in any one of claims 1 – 3 in crystalline or partially crystalline form.
- 5 5. A salt as claimed in any one of claims 1 – 4 either in the form of a mixed salt together with a pharmaceutically inactive counterion.
- 10 6. A salt as claimed in any one of claims 2 – 4 wherein the pharmaceutically inactive counterion is  $[\text{CaCl}]^+$ .
- 20 7. A pharmaceutical formulation comprising a compound according to any one of claims 1 to 6 in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.
- 25 8. A method of treating or preventing lipid disorders (dyslipidemia) whether or not associated with insulin resistance comprising the administration of a compound according to any one of claims 1 to 6 to a mammal in need thereof.
9. The use of a compound according to any one of claims 1 to 6 in the manufacture of a medicament for the treatment of lipid disorders (dyslipidemia) whether or not associated with insulin resistance.

BEST AVAILABLE COPY

- 35 -

10. A method of treating or preventing type 2 diabetes comprising the administration of an effective amount of a compound of formula I according to any one of claims 1 to 6 to a mammal in need thereof.

11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6 combined with another therapeutic agent that is useful in the treatment of disorders associated with the development and progress of atherosclerosis such as hypertension, hyperlipidaemias, dyslipidaemias, diabetes and obesity.

10

BEST AVAILABLE COPY